RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as investors reacted to the FDA’s decision to review compounded peptide therapies. Trading volume reached 74.6 million shares, about 111% above its three-month average of 35.3 million shares. Hims & Hers Health IPO'd in 2019 and has grown 175% since going p…

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?

The post BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming? appeared first on 24/7 Wall St.. Quick Read Bank of America raised its price target on Hims & Hers Health (HIMS) to $25 from $21 while maintaining a Neutral rating, citing the FDA’s decision to evaluate wellness peptides that could create new revenue streams and allow the company to repurpose existing GLP-1 manufacturing c…

Hims & Hers stock rises 14% as FDA schedules peptide compounding review

The FDA will ask an outside panel to weigh whether 7 popular peptides can be produced by compounding pharmacies, opening a potential new market for Hims & Hers

Hims & Hers Stock Surges 13% on FDA Peptide Review Optimism and Telehealth Momentum

NEW YORK — Shares of Hims & Hers Health Inc. climbed sharply in morning trading Friday as investors bet that potential regulatory relief on compounded peptides could strengthen the telehealth company's weight-loss offerings and broader platform growth.